Increased risk of complicated CMV infection with the use of mycophenolate mofetil in allogeneic stem cell transplantation (Q44038912)

29 November 2017

title

Increased risk of complicated CMV infection with the use of mycophenolate mofetil in allogeneic stem cell transplantation (English)

1 reference

29 November 2017

L Hambach

1

1 reference

29 November 2017

M Stadler

2

1 reference

29 November 2017

E Dammann

3

1 reference

29 November 2017

A Ganser

4

1 reference

29 November 2017

B Hertenstein

5

1 reference

29 November 2017

language of work or name

English

0 references

publication date

1 June 2002

1 reference

Bone Marrow Transplantation

29 November 2017

published in

1 reference

29 November 2017

volume

29

1 reference

29 November 2017

issue

11

1 reference

29 November 2017

page(s)

903-906

1 reference

Mycophenolate mofetil for the prophylaxis of acute GVHD in HLA-mismatched bone marrow transplant patients.

29 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703583

Mycophenolate mofetil for the treatment of acute and chronic GVHD in bone marrow transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703583

Mycophenolate mofetil increases cytomegalovirus invasive organ disease in renal transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703583

The influence of mycophenolate mofetil on the incidence and severity of primary cytomegalovirus infections and disease after renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703583

Rapid immunodiagnosis of active cytomegalovirus infection by monoclonal antibody staining of blood leucocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703583

Risk for cytomegalovirus disease in patients receiving polymerase chain reaction-based preemptive antiviral therapy after allogeneic stem cell transplantation depends on transplantation modality

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703583

Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703583

Development of cytomegalovirus resistance to ganciclovir after oral maintenance treatment in a renal transplant recipient.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703583

Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703583

7 January 2021

Risk factors for cytomegalovirus infection after human marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703583

7 January 2021

Patient cytomegalovirus seropositivity with or without reactivation is the most important prognostic factor for survival and treatment-related mortality in stem cell transplantation from unrelated donors using pretransplant in vivo T-cell depletion

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703583

7 January 2021

Reduced risk of persisting cytomegalovirus pp65 antigenemia and cytomegalovirus interstitial pneumonia following allogeneic PBSCT

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703583

7 January 2021

Identifiers

DOI

10.1038/SJ.BMT.1703583

1 reference

Dimensions Publication ID

29 November 2017

1021016974

0 references

1 reference